Hemispherian, a clinical-stage oncology company, announced on April 8, 2026, the initiation of a Phase 1/2a clinical trial for its lead candidate, GLIX1, marking a significant milestone in the development of targeted therapies for recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.
The study, identified as NCT07464925, is being conducted in collaboration with BioLineRx (NASDAQ:BLRX).
The trial represents the first time this novel mechanism—restoring TET2 activity to drive selective DNA damage in tumor cells—will be tested in a human clinical setting.
GLIX1 is an orally available, first-in-class small molecule designed to exploit the suppressed TET2 activity often found in aggressive cancers.
By activating this enzyme, GLIX1 induces tumor-selective DNA damage, offering a highly differentiated approach to targeting the DNA damage response (DDR) while sparing healthy tissue.
The decision to focus on glioblastoma as the primary indication stems from the disease's aggressive nature and the critical lack of effective treatment options for patients facing recurrence.
GBM is characterized by significantly suppressed TET2 activity, making it a prime candidate for GLIX1’s mechanism of action.
The multi-center trial will be hosted at three of the United States' premier oncology institutions.
NYU Langone Health has officially initiated patient enrollment under the leadership of Dr. Alexandra Miller.
The trial will also expand to Northwestern University, led by renowned neuro-oncologists Dr. Roger Stupp and Dr. Ditte Primdahl, and the Moffitt Cancer Center under Dr. Patrick Grogan.
Preclinical models, including orthotopic in vivo GBM studies, have consistently demonstrated that GLIX1 can penetrate the brain's protective barrier to reach the tumor site effectively.
This has been a historical hurdle for many small-molecule oncology candidates.